MedTrace Logo

Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

NCT02035215 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-03-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia

Conditions

  • Hyperlipidemia, Familial Combined

Interventions

DRUG

Atorvastatin 20mg

DRUG

Omega-3-acids ethylesters 90 4g

OTHER

Placebo(Omega-3-acids ethylesters 90)

Sponsors & Collaborators

  • Kuhnil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong Seog Seo, Ph.D. · Korea University Guro Hospital

  • Hee Kyoung Cheon, Ph.D. · Uijongbu St. Mary's Hospital

  • Sang-Ho Jo, Ph.d. · Hallym University Medical Center

  • Mi-Seung Shin, Ph.D · Gachon University Gil Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02035215 on ClinicalTrials.gov